Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

ittee for Orphan Medicinal Products of the European Medicines Agency, or EMEA, granted orphan medicinal product designation to PDX for the treatment of patients with PTCL

About the Data Monitoring Committee (DMC)

The DMC is comprised of independent medical experts and was established by Allos as part of the Company's compliance with good clinical practice guidelines. The DMC is responsible for monitoring the on-going safety of patients participating in the PROPEL trial and for conducting formal interim safety assessments of trial results.

About Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse and uncommon group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin's lymphoma, or about 7,100 patients annually. The average five-year survival rate for PTCL patients is approximately 25%. There are currently no pharmaceutical agents approved for use in the treatment of either first-line or relapsed or refractory PTCL.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. The Company believes these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and certain other DHFR inhibitors.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a piv
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... 16, 2012 An estimated one in 1,000 women and men ... treatment or no treatment at all. What will it take to ... , the global bleeding disorders community will spread the message to ... work toward a day when treatment will be available for all ...
... (NYSE Amex: MHH ) ("Mastech"), a ... scheduled a conference call to discuss the results of ... conference call will occur on Wednesday, April 25, ... be hosted by Mr. Kevin Horner, CEO, and ...
Cached Medicine Technology:World Hemophilia Day -- April 17 2Mastech Holdings, Inc. to Discuss First Quarter 2012 Financial Results on April 25, 2012 2
(Date:8/29/2015)... Church, VA (PRWEB) , ... August 30, 2015 ... ... **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... much more than a simple digital handwritten signature. , Clinical trial ...
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... with stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed ... to improve treatment outcomes. This localized treatment seems to address the symptoms ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, masks, supplies, ... CPAP equipment more affordable by offering shipping at no cost to you, directly to ... orders of any size. My Cpap Store is located in Las Vegas, Nevada. , ...
(Date:8/28/2015)... , ... August 28, 2015 , ... For Dallas, the ... taking part with their subsidiary USPI Tenet Health. , The American Heart Association hosts ... disease and stroke. They believe that together, a difference can be made. Walkers can ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... ... technology for sales assessment testing helps employers customize a sales ability test for Customer ... 10 free sales ability tests , ... (PRWEB) May 13, 2010 -- Good sales people and good customer ...
... 13, 2010) -- A national summit of medical professionals ... of consensus scan techniques as a way of addressing ... common medical imaging procedure that uses X-rays to show ... together some of the world,s leading experts in CT ...
... Michigan survey, most said they,d try to get to ER on ... aren,t familiar with the symptoms of a stroke and most who ... stroke occurred, a new survey finds. , "If you know the ... them, that doesn,t do you much good," said study author Chris ...
... ... Diversified’s Information Lifecycle Solutions in the Financial, Insurance & Healthcare Industries, , ... Scranton, Pa. ... of document and information lifecycle solutions, announced today that it has formed a ...
... new study led by researchers from Mayo Clinic in ... patients with non-Hodgkin,s lymphoma who smoked, consumed alcohol or ... survival, compared to patients who did not have these ... and demographic factors, and also when considering only deaths ...
... for males tying the knot with younger females, study found , ... to nine years their junior could be upping their odds of ... significantly younger guy raises a woman,s risk of death by 20 ... of Demography . , Not that marrying much older men ...
Cached Medicine News:Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 2Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 3Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 4Health News:Symposium focuses on patient safety in CT scanning 2Health News:Symposium focuses on patient safety in CT scanning 3Health News:Too Many Wouldn't Call 911 If Stroke Hit 2Health News:Too Many Wouldn't Call 911 If Stroke Hit 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 2Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 4Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 2Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 3Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 4Health News:Women Who Marry Younger Men May Die Earlier 2
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
... 7.5 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: